Ontology highlight
ABSTRACT: Background
Renal impairment is one of the common characteristics of multiple myeloma (MM) and makes management of MM more complicated. Even though monoclonal antibodies targeting CD38 have wildly succeeded in treating MM, the addition of anti-CD38 monoclonal antibodies to standard therapy to treat MM patients with renal insufficiency is still poorly studied.Objectives
This study aims to evaluate whether using anti-CD38 monoclonal antibody-based immunotherapy would improve the prognosis of MM patients with renal insufficiency.Design
This is a systematic review and meta-analysis.Data sources and methods
We searched Scopus, PubMed, Cochrane Central Register of Controlled Trials (CENTRAL), Ovid MEDLINE, Ovid Embase, and Web of Science Core Collection for randomi
SUBMITTER: Bai H
PROVIDER: S-EPMC11831653 | biostudies-literature | 2025
REPOSITORIES: biostudies-literature